Form 8-K - Current report:
SEC Accession No. 0001437749-22-027319
Filing Date
2022-11-14
Accepted
2022-11-14 16:33:34
Documents
15
Period of Report
2022-11-10
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20221113_8k.htm   iXBRL 8-K 46026
2 EXHIBIT 99.1 ex_446672.htm EX-99.1 17676
7 nb01.jpg GRAPHIC 4745
  Complete submission text file 0001437749-22-027319.txt   210551

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nby-20221110.xsd EX-101.SCH 3594
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20221110_def.xml EX-101.DEF 11530
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20221110_lab.xml EX-101.LAB 15415
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20221110_pre.xml EX-101.PRE 11686
9 EXTRACTED XBRL INSTANCE DOCUMENT nby20221113_8k_htm.xml XML 2567
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 221386501
SIC: 2834 Pharmaceutical Preparations